BioMarin Pharmaceutical $850 million debut senior notes offering
We advised the representative of the initial purchasers
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Coherus Oncology $50 million follow-on offering
We advised the joint book-running managers and representatives of the underwriters on the offering
Rhône Capital acquisition of Invacare
We advised Highbridge Capital, as an Invacare secured lender and noteholder, on the transaction
Ascletis Pharma HK$843.5 million placement of shares
We advised the placing agent on the transaction
AgomAb Therapeutics $200 million IPO
We advised the representatives of the several underwriters on the IPO
Eikon Therapeutics $381 million IPO
We advised the representatives of the several underwriters on the IPO
Maze Therapeutics $200 million at-the-market offering
We advised the sales agent on the offering
Perspective Therapeutics $175 million equity offering
We advised the representatives of the underwriters on the transaction
Roche Holdings $1.9 billion notes offering
We advised Roche on the offering comprising three tranches of notes
bit.bio $50 million Series C equity financing
We are advising the company on the funding round